CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / ELI Lilly & CO (LLY) / orforglipron
Forward catalyst · LLY

orforglipron

Sponsor ELI Lilly & CO · listed as LLY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

orforglipron is a clinical-stage drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 4 forward catalysts for it — the nearest is a readout expected Nov 2026 (month precision, medium confidence), tied to trial NCT06649045. The asset is in Phase 3 and currently active not recruiting, studied in OSA. It appears across 16 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-11-30
As disclosedNov 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06649045
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorEli Lilly and Company
Listed asLLY
Condition(s)OSA; Overweight or Obesity

All tracked catalysts for orforglipron

DateEventConfidenceTrial
2026-11-30READOUTmediumNCT06649045
2027-02-28READOUTmediumNCT06672549
2027-05-31READOUTmediumNCT07613307
2027-08-31READOUTmediumNCT06972459
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More LLY catalysts